Infinity Pharmaceuticals, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-10-30: Form 8-K; Period of report 2019-10-30; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2019-08-22: Form 8-K; Period of report 2019-08-16; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 5.02.
- 2019-07-30: Form 8-K; Period of report 2019-07-29; Description 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; Details 1.01.
- 2019-06-28: Form 8-K; Period of report 2019-06-28; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-10-30 | 8-K | 2019-10-30 | 2.02 Results of Operations and Financial Condition | 2.02 On October 30, 2019, the Company issued a press release announcing its results for the quarter ended September 30, 2019 and will conduct a previously announced, publicly available conference call to discuss those results. | form8-kxfinancials.htm |
| 2019-08-22 | 8-K | 2019-08-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 (b) On August 16, 2019, Samuel Agresta, M.D., M.P.H., Chief Medical Officer of Infinity Pharmaceuticals, Inc. (the “Company”) and a named executive officer of the Company, notified the Company of his decision to resign effective September 13, 2019. 8.01 On August 22, 2019, the Company issued a press release announcing the resignation of Dr. Agresta as Chief Medical Officer of the Company and his election to the Board. | d797188d8k.htm |
| 2019-07-30 | 8-K | 2019-07-29 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition | 1.01 On July 29, 2019, Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Amended and Restated Capital on Demand™ Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC and B. Riley FBR, Inc. (each, an “Agent” and collectively, the “Agents”), pursuant to which the Company may offer and sell shares of its common stock, $0.001 par value per share, having an aggregate offering price of up to $20,000,000 (the “Shares”) from time to time through the Agents (the “Offering”). 2.02 On July 30 2019, the Company issued a press release announcing its results for the quarter ended June 30, 2019 and will conduct a previously announced, publicly available conference call to discuss those results. | d745019d8k.htm |
| 2019-06-28 | 8-K | 2019-06-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 On June 28, 2019, Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Capital on Demand™ Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC, as agent (“JonesTrading”), pursuant to which the Company may offer and sell shares of its common stock, $0.001 par value per share, having an aggregate offering price of up to $20,000,000 (the “Shares”) from time to time through JonesTrading (the “Offering”). | d741496d8k.htm |
| 2019-06-13 | 8-K | 2019-06-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 At the annual meeting of stockholders of Infinity Pharmaceuticals, Inc. (the “Company”) held on June 13, 2019 (the “2019 Annual Meeting”), the Company’s stockholders approved the 2019 Equity Incentive Plan (the “2019 Plan”), which had previously been adopted by the Company’s Board of Directors (the “Board”) subject to stockholder approval. | d752269d8k.htm |
| 2019-05-07 | 8-K | 2019-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2019, we issued a press release announcing our results for the quarter ended March 31, 2019 and will conduct a previously announced, publicly available conference call to discuss those results. | d725048d8k.htm |
| 2019-04-08 | 8-K | 2019-04-05 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth above in Item 1.01 of this Current Report on Form 8-K regarding the Lease is incorporated into this Item 2.03 by reference. | d675725d8k.htm |
| 2019-03-14 | 8-K | 2019-03-14 | 2.02 Results of Operations and Financial Condition | 2.02 On March 14, 2019, we issued a press release announcing our results for the year ended December 31, 2018 and will conduct a previously announced, publicly available conference call to discuss those results. | d721300d8k.htm |
| 2019-03-06 | 8-K | 2019-03-04 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 On March 5, 2019, Infinity Pharmaceuticals, Inc. (the “Company”) entered into a purchase and sale agreement (the “Purchase Agreement”) with HealthCare Royalty Partners III, L.P. (the “Purchaser”) providing for the acquisition by the Purchaser of the Company’s interest in certain royalty payments (the “Purchased Assets”) based on worldwide annual net sales of products containing IPI-145 (such products, collectively, the “Licensed Product” and such acquisition, the “Transaction”) pursuant to that certain Amended and Restated License Agreement, dated as of November 1, 2016 (the “License Agreement”), by and between the Company and Verastem, Inc. (“Verastem”). 2.03 The information provided in Item 1.01 relating to the Transaction is hereby incorporated by reference into this Item 2.03. 8.01 On March 6, 2019, the Company issued a press release announcing the Transaction. | d715936d8k.htm |
| 2019-01-28 | 8-K | 2019-01-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On January 26, 2019, pursuant to our Corporate Governance Guidelines, Ian Smith tendered his resignation from our Board of Directors (the “Board”) following a change in his employment status, which our Board accepted effective January 27, 2019. | d666025d8k.htm |
| 2019-01-07 | 8-K | 2019-01-07 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2018, the Company announced on January 7, 2019 that it expects to report that it had approximately $58.6 million in cash and investments (unaudited) as of December 31, 2018. 8.01 On January 7, 2019, the Company issued a press release announcing its 2019 business goals and financial guidance. | d687449d8k.htm |